極論で語る腎臓内科　第2版

出版社： 丸善出版
著者：
発行日： 2022-09-30
分野： 臨床医学：内科  >  腎臓
ISBN： 9784621307458
シリーズ： 極論で語るシリーズ
電子書籍版： 2022-09-30 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

3,850 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,850 円(税込)

購入する

商品紹介

著者の今井直彦医師の「極論」は、まず膨大なドラフト原稿があり、次に詳細な取捨選択がはじまり（日の目をみなかった原稿の数々…）、そして最後に「極論」を燻しだされます。臨床における腎臓疾患という現象を考えに考えた末の、そのいぶし銀の視点が「極論」。シリーズの中でもよりロジカル、基礎医学領域に依拠した腎臓内科編。「尿所見の見方」「高血圧」「尿路結石」の章を新設し、全章見直してさらに「極論」を推し進めた大改訂2版をご期待ください。

目次

  • 第1部　腎臓内科，まずはここから始めよう
    　1章　急性腎障害［acute kidney injure; AKI］
    　　極論1　「AKI は予防につきる」と云うかそれしかない
    　　極論2　腎臓の敵は腎臓にあり；AKI ハイリスクはCKD
    　　極論3　数値，特にFE Na に振り回されない
    　　極論4　利尿薬は諦めが肝腎
    　2章 尿所見の見方［interpretation of urine Tests］
    　　極論1　尿検査は最も「優しい」検査である
    　　極論2　血尿＝腎臓内科の病気ではない
    　　極論3　軽度の蛋白尿も無視してはならない
    　　極論4　多尿は稀である
    　　極論5　尿沈渣を忘れるな

    第2部　腎臓は体内の水分のバランスを司る
    　3章　脱水と浮腫［dehydration and edema］
    　　極論1　ナトリウムが大事
    　　極論2　脱水の評価は定点でなく経時的に
    　　極論3　脱水はすばやく，浮腫はゆっくり治療する
    　　極論4　心不全と腎不全で利尿薬の使い方は違う！
    　4章　輸液［intravenous fluid］
    　　極論1　不必要な輸液は有害です
    　　極論2　基本的には5%ブドウ糖液と生理食塩水で対応する
    　　極論3　輸液成分の体内での分布を予測する
    　　極論4　いわゆる「維持液」はじつは維持輸液として不適切

    第3部　酸に傾こうとする血液をアルカリに
    　5章　酸塩基平衡の基礎［overview of acid-base balance］
    　　極論1　マイナスイオン？　いいえ，体は酸性へと向かっています
    　　極論2　その酸をまず緩衝してくれるのは炭酸と重炭酸
    　　極論3　最終的な酸の腎排泄はアンモニウムイオンとともに
    　6章　血液ガスの読み方［interpretation of arteriol blood gas］
    　　極論1　血液ガスは五つのステップで読む
    　　極論2　数値だけでなく，必ず総合判断
    　　極論3　呼吸性アシドーシスと呼吸性アルカローシス「だけ」は混在しない
    　　極論4　pH が極端に動いていたら混合性の異常
    　　極論5　食わずぎらいをなくして，スチュワート法も使ってみよう
    　　極論6　低アルブミン血症のときもスチュワート法で安心
    　7章　代謝性アルカローシス［metabolic alkalosis］
    　　極論1　じつは頻度が高くて怖い
    　　極論2　代謝性アルカローシスは「発生」して「維持」される
    　　極論3　何となく調子が悪い？　それはアルカローシスではないですか？
    　　極論4　尿中クロール濃度を測定して考えよう
    　8章　代謝性アシドーシス［metabolic acidosis］
    　　極論1　代謝性アシドーシスの危機は常に存在する
    　　極論2　薬物中毒を疑ったら浸透圧ギャップ
    　　極論3　酸排泄はアンモニウムイオンで
    　　極論4　腎臓は重炭酸イオンを拾って，不揮発性酸を捨てる臓器

    第4部　身近な検査項目を深く捉える
    　9章　低ナトリウム血症と高ナトリウム血症［hypo and hypernatremia］
    　　極論1　軽度の低Na血症も無視できない（真の無症候性の低Na血症は少ない）
    　　極論2　低Na血症を見たらADH を意識する
    　　極論3　症候性の低Na血症は緊急疾患である
    　　極論4　高Na血症はふつうじゃない！
    　10章　カリウム［potassium］
    　　極論1　カリウムの調節は集合管の「排泄」
    　　極論2　低カリウム値は病歴抜きには語れない
    　　極論3　尿中のカリウム濃度を追え
    　　極論4　心電図変化よりも「値」を信じよう

    第5部　最後に慢性期の腎臓管理を押さえる
    　11章　慢性腎臓病［chronic kindey disease; CKD］
    　　極論1　CKD では腎機能だけではなく蛋白尿に注目
    　　極論2　本当は怖いCKD
    　　極論3　血清クレアチニン値が高くてもRAS 阻害薬にチャレンジしよう
    　12章　高血圧［hypertension］
    　　極論1　どんどん下がる降圧目標（これからは130/80）
    　　極論2　高血圧かどうかは家庭血圧で決める！　
    　　極論3　非薬物療法は治療にも予防にもなる
    　　極論4　二次性高血圧を疑う
    　　極論5　高血圧も低血圧も腎臓にはよくない
    　13章　尿路結石症［urolithiasis］
    　　極論1　再発予防こそ腎臓内科医の役割
    　　極論2　何度でもしよう「結石分析」
    　　極論3　必ずしたい24時間蓄尿検査
    　　極論4　飲水は"処方薬"
    　　極論5　尿酸結石ならラッキーである（あるいは，尿と結石は尿pHの病気）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1部 腎臓内科, まずはここからはじめよう

P.21 掲載の参考文献
1) Himmelfarb J, Ikizler TA. Acute kidney Injury : changing lexicography, definitions, and epidemiology. Kidney Int. 2007 May ; 71 (10) : 971-6.
PubMed
2) Bellomo R, Ronco C, et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and Information technology needs : the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care. 2004 Aug ; 8 (4) : R204-12.
PubMed
3) https://kdigo.org/wp-content/uploads/2020/10/KDIGO-2020-Diabetes-in-CKD-GL.pdf.
 
4) Dennen P, Douglas IS, et al. Acute kidney injury in the intensive care unit : an update and primer for the intensivist. Crit Care Med. 2010 ; 38 (1) : 261-75.
PubMed
5) Coca SG, Peixoto AJ, et al. The prognostic importance of a small acute decrement in kidney function in hospitalized patients : a systematic review and meta-analysis. Am J Kidney Dis. 2007 ; 50 (5) : 712-20.
PubMed
6) Liangos O, Wald R, et al. Epidemiology and outcomes of acute renal failure in hospitalized patients : a national survey. Clin J Am Soc Nephrol. 2006 ; 1 (1) : 43-51.
PubMed
7) Anderson S, Eldadah B, et al. Acute kidney injury in older adults. J Am Soc Nephrol. 2011 ; 22 (1) : 28-8.
PubMed
8) Kellum JA, Chawla LS, et al. The Effects of Alternative Resuscitation Strategies on Acute Kidney Injury in Patients with Septic Shock. Am J Respir Crit Care Med. 2016 ; 193 (3) : 281-7.
PubMed
9) Cerda J, Lameire N, et al. Epidemiology of acute kidney injury. Clin J Am Soc Nephrol. 2008 ; 3 (3) : 881-6.
PubMed
10) Kellum JA, Sileanu FE, et al. Recovery after Acute Kidney Injury. Am J Respir Crit Care Med. 2017 ; 195 (6) : 784-91.
PubMed
11) Palevsky PM. Chronic-on-acute kidney injury. Kidney Int. 2012 ; 81 (5) : 430-1.
PubMed
12) Lo LJ, Go AS, et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int. 2009 ; 76 (8) : 893-9.
PubMed
13) Pannu N. Bidirectional relationships between acute kidney injury and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013 ; 22 (3) : 351-6.
PubMed
14) Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med. 2007 ; 357 (8) : 797-805.
PubMed
15) Myers BD, Moran SM. Hemodynamically mediated acute renal failure. N Engl J Med. 1986 ; 314 (2) : 97-105.
PubMed
16) National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy : 2015 update. Am J Kidney Dis. 2015 Nov ; 66 (5) : 884-930.
PubMed
17) Jo SK, Rosner MH, et al. Pharmacologic treatment of acute kidney injury : why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol. 2007 ; 2 (2) : 356-65.
 
18) STARRT-AKI Investigators, et al. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med. 2020 ; 383 (3) : 240-51.
PubMed
19) Hilton R. Acute renal failure. BMJ. 2006 ; 333 (7572) : 786-90.
PubMed
20) Himmelfarb J, Joannidis M, et al. Evaluation and initial management of acute kidney injury. Clin J Am Soc Nephrol. 2006 ; 3 (4) : 962-7.
 
21) Bellomo R, Kellum JA, et al. Acute kidney injury. The Lancet. 2012 ; 380 (9843) : 756-66.
 
22) Mullens W, Abrahams Z, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009 ; 53 (7) : 589-96.
PubMed
23) Shamseddin MK, Parfrey PS. Mechanisms of the cardiorenal syndromes. Nat Rev Nephrol. 2009 ; 5 (11) : 641-9.
PubMed
24) Beaubien-Souligny W, Benkreira A, et al. Alterations in Portal Vein Flow and Intrarenal Venous Flow Are Associated With Acute Kidney Injur y After Cardiac Surgery : A Prospective Observational Cohort Study. J Am Heart Assoc. 2018 ; 7 (19) : e009961.
 
25) Lassnigg A, Donner E, et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol. 2000 ; 11 (1) : 97-104.
PubMed
26) AKI (急性腎障害) 診療ガイドライン作成委員会 (編). AKI (急性腎障害) 診療ガイドライン. 東京医学社, 2016.
 
27) Cantarovich F, Rangoonwala B, et al. High-dose furosemide for established ARF : a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis. 2004 ; 44 (3) : 402-9.
PubMed
28) Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ. 2006 ; 333 (7565) : 420.
PubMed
29) Mehta RL, Pascual MT, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002 ; 288 (20) : 2547-53.
PubMed
30) Chawla LS, Davison DL, et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care. 2013 ; 17 (5) : R207.
PubMed
31) Singri N, Ahya SN, et al. Acute renal failure. JAMA. 2003 ; 289 (6) : 747-51.
PubMed
32) Licurse A, Kim MC, et al. Renal ultrasonography in the evaluation of acute kidney injury : developing a risk stratification framework. Arch Intern Med. 2010 ; 170 (21) : 1900-7.
PubMed
P.44 掲載の参考文献
1) 日本臨床検査学教育協議会 (監修), 市村輝義, 辰喜亮介 (編著). 臨床検査学実習書シリーズ 一般検査学実習書. 2011, 医歯薬出版.
 
2) UpToDate (https://www.uptodate.com/contents/search).
 
3) 日本臨床検査医学会ガイドライン作成委員会 (編). 臨床検査のガイドライン JSLM2015 検査値アプローチ/症候/疾患. 2015, 宇宙堂八木書店.
 
4) Iseki K, Iseki C, et al. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996 ; 49 (3) : 800-5.
 
5) Kang KK, Choi JR, et al. Clinical significance of subjective foamy urine. Chonnam Med J 2012 ; 48 (3) : 164-8.
PubMed
6) Constantiner M, Sehgal AR, et al. A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. Am J Kidney Dis. 2005 ; 45 (5) : 833-41.
PubMed
7) Abe M, Okada M, et al. Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map. J Diabetes Res. 2016 ; 1-9.
 
8) Rapoport A, Husdan H, et al. A standardized test of renal concentrating capacity in adults with some results in essential hypertension. Can Med Assoc J. 1969 ; 101 (12) : 93-8.
PubMed
9) Souza AC, Zatz R, et al. Is urinary density an adequate predictor of urinary osmolality? BMC Nephrol. 2016 ; 16 : 46.
 
10) https://www.matubara.tokushukai.or.jp/medical/urology/urology-sub04.html.
 
11) Paul Kimmel, Mark Rosenberg. Chronic Renal Disease 2nd Edition. 2019. ELSEVIER.
 
12) BELLET S, DREIFUS LS, et al. Urinary osmolar concentration in the hydropenic state as a measure of renal tubular function : a test for early renal impairment : preliminary report. Am.J.Med Sci. 1957 ; 233 (2) : 121-5.
PubMed
13) Wise GJ, Schlegel PN. Sterile pyuria. N Engl J Med. 2015 ; 372 (11) : 1048-54.
PubMed
14) Perazella MA, Coca SG, et al. Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol. 2010 ; 5 (3) : 402-8.
PubMed
15) Muriithi AK, Nasr SH, et al. Utility of urine eosinophils in the diagnosis of acute interstitial nephritis. Clin J Am Soc Nephrol. 2013 Nov ; 8 (11) : 1857-62.
PubMed

第2部 腎臓は体内の水分のバランスを司る

P.69 掲載の参考文献
1) McGee S, Abernethy WB 3rd, et al. The rational clinical examination. Is This Patient Hypovolemic? JAMA. 1999 ; 281 (11) : 1022-9.
PubMed
2) Marik PE, Baram M, et al. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 2008 ; 134 (1) : 172-8.
PubMed
3) Marik PE, Monnet X, et al. Hemodynamic parameters to guide fluid therapy. Ann Intensive Care. 2011 ; 1 (1) : 1.
PubMed
4) Cho S, Atwood JE. Peripheral edema. Am J Med. 2002 ; 113 (7) : 580-6.
PubMed
5) Schrier RW. Manual of Nephrology. Lippincott Williams & Wilkins. 2008.
 
6) Paterna S, Pasquale PD, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure : a double-blind study. J Am Coll Cardiol. 2005 ; 45 (12) : 1997-2003.
 
7) Griffin M, Soufer A, et al. Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure : A U.S. Center's Experience. JACC Heart Fail. 2020 Mar ; 8 (3) : 199-208.
 
8) Rudy DW, Voelker JR, et al. Loop diuretics for chronic renal insufficiency : a continuous infusion is more efficacious than bolus therapy. Ann Intern Med. 1991 ; 115 (5) : 360-6.
PubMed
9) Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012 ; 6 (5) : 299-308.
PubMed
P.88 掲載の参考文献
1) Yunos NM, Bellomo R, et al. Association between a chloride-liberal vs. chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 ; 308 (15) : 1566-72.
PubMed
2) Yunos NM, et al. Bench-to-bedside review : Chloride in critical illness. Crit Care. 2010 ; 14 (4), 226.
PubMed
3) Semler MW, Self WH, et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med. 2018 ; 378 (9), 829-39.
PubMed
4) Finfer S, Micallef S, et al. Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults. N Engl J Med. 2022 Mar 3 ; 86 (9) : 815-26.
 
5) Hammond NE, et al. Balanced Crystalloids versus Saline in Critically Ill Adults : A Systematic Review with Meta-Analysis. NEJM Evid. 2022 ; 1 (2) : 10.1056/evidoa2100010.
 
6) Perner A, Haase N, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012 ; 367 (2), 124-34.
 
7) Finfer S, Bellomo R, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004 ; 350 (22), 2247-56.
PubMed
8) Myburgh JA, Finfer S, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012 ; 367 (20), 1901-11.
 
9) Rivers E, Nguyen B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 ; 345 (19), 1368-77.
 
10) Boyd JH, Forbes J, et al. Fluid resuscitation in septic shock : a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011 Feb ; 39 (2) : 259-65.
PubMed
11) Evans L, et al. Surviving sepsis campaign : international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov ; 47 (11) : 1181-1247.
PubMed

第3部 酸に傾こうとする血液をアルカリに

P.105 掲載の参考文献
1) Rennke HG, Denker BM. Renal Pathophysiology : The Essentials. 2nd ed. Lippincott Williams & Wilkins. 2007.
 
P.131 掲載の参考文献
1) Hodgkin JE, Soeprono FF, et al. Incidence of metabolic alkalemia in hospitalized patients. Crit Care Med. 1980 ; 8 (12), 725-8.
PubMed
2) Story, DA. Stewart Acid-Base : A Simplified Bedside Approach. Anesth Analg. 2016 ; 123 (2), 511-5.
PubMed
3) Kishen R, Honore PM, et al. Facing acid-base disoders in the third millennium-the Stewart approach revisited. Int J Nephrol Renovasc Dis. 2014 ; 7 : 209-17.
 
4) Kraut JA, Nagami GT. The serum anion gap in the evaluation of acid-base disorders : what are its limitations and can its effectiveness be improved? Clin J Am Soc Nephrol. 2013 ; 8 (11), 2018-24.
PubMed
P.146 掲載の参考文献
1) Hodgkin JE, Soeprono FF, et al. Incidence of metabolic alkalemia in hospitalized patients. Crit Care Med. 1980 ; 8 (12) : 725-8.
PubMed
2) Anderson LE, Henrich WL. Alkalemia-associated morbidity and mortality in medical and surgical patients. South Med J. 1987 ; 80 (6) : 729-33.
PubMed
3) Van Goidsenhoven GM, Gray OV, et al. The effect of prolonged administration of large doses of sodium bicarbonate in man. Clin Sci. 1954 ; 13 (3) : 383-401.
PubMed
4) Patel AM, Goldfarb S. Got calcium? Welcome to the calcium-alkali syndrome. J Am Soc Nephrol. 2010 ; 21 (9) : 1440-3.
 
5) Emmett M. Metabolic Alkalosis : A Brief Pathophysiologic Review. Clin J Am Soc Nephrol. 2020 ; 15 (12) : 1848-56.
PubMed
6) Luke RG, Galla JH. It is chloride depletion alkalosis, not contraction alkalosis. J Am Soc Nephrol. 2012 ; 23 (2) : 204-7.
 
P.167 掲載の参考文献
1) Kraut JA, Madias NE. Metabolic acidosis : pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010 ; 6 (5) : 274-85.
PubMed
2) Kraut JA, Madias NE. Metabolic acidosis : pathophysiology, diagnosis and management. Nat. Rev. Nephrol. 2010 ; 6 (5) : 480-4.
 
3) Mehta AN, Emmett JB, et al. GOLD MARK : an anion gap mnemonic for the 21st Century. Lancet. 2008 ; 372 (9642) : 892.
 

第4部 身近な検査項目を深く捉える

P.191 掲載の参考文献
1) Renneboog B, Much M, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006 Jan ; 119 (1) : 71.e1-8.
 
2) Leung AA, McAlister FA, et al. Preoperative hyponatremia and perioperative complications. Arch Intern Med. 2012 ; 172 (19) : 1474-81
 
3) Verbalis JG, Goldsmith SR, et al. Diagnosis, evaluation, and treatment of hyponatremia : expert panel recommendations. Am J Med.2013 ; 126 (10 Suppl 1) : S1-S42.
 
4) Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007 ; 356 (20) : 2064-72.
PubMed
5) Sterns RH, Hix JK, et al. Treating profound hyponatremia : a strategy for controlled correction. Am J Kidney Dis. 2010 ; 56 (4) : 774-9.
PubMed
6) Moritz ML, Ayus JC. 100 cc 3% sodium chloride bolus : a novel treatment for hyponatremic encephalopathy. Metab Brain Dis. 2010 ; 25 (1) : 91-6.
PubMed
7) 内田俊也. 水電解質異常. 日本腎臓学会誌 2002 ; 44 (1) : 18-28.
 
8) Robertson GL, Aycinena P, et al. Neurogenic disorders of osmoregulation. Am J Med. 1982 ; 72 (2) : 339-53.
PubMed
9) Adrogue HJ, Madias NE. Hypernatremia. N Engl J Med. 2000 ; May 18 ; 342 (20) : 1493-9.
 
P.213 掲載の参考文献
1) Gennari FJ. Hypokalemia. N Engl J Med. 1998 ; 339 (7), 451-8.
PubMed
2) Giebisch G, Krapf R, et al. Renal and extrarenal regulation of potassium. Kidney Int. 2007 ; 72 (4) : 397-410.
PubMed
3) Palmer BF. A physiologic-based approach to the evaluation of a patient with hypokalemia. Am J Kidney Dis. 2010 ; 56 (6) : 1184-90.
 
4) Muthucumarana K, Howson P, et al. The Relationship Between Presentation and the Time of Initial Administration of Antibiotics With Outcomes of Peri t onitis in Peritoneal Dialysis Patients : The PROMPT Study. Kidney Int Rep. 2016 Jun 11 ; 1 (2) : 65-72.
 
5) McKean SC, Bennett AL, et al. Hospital Medicine : Just The Facts. McGraw-Hill Professional, 2008.
 
6) Greenfeld D, Mickley D, et al. Hypokalemia in outpatients with Eating disorders. Am J Psychiatry. 1995 ; 152 (1) : 60-3.
PubMed
7) Ethier JH, Kamel KS, et al. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kidney Dis. 1990 ; 15 (4) : 309-15.
PubMed
8) UpToDate (https://www.uptodate.com/contents/causes-and-evaluation-ofhyperkalemia-in-adults?search=TTKG&source=search_result&selectedTitle=1~3&usage_type=default&display_rank=1).
 
9) Kamel KS, Halperin ML. Intrarenal urea recycling leads to a higher rate of renal excretion of potassium : an hypothesis with clinical implications. Curr Opin Nephrol Hypertens. 2011 ; 20 (5) : 547-54.
PubMed
10) Sterns RH, Cox M, et al. Internal potassium balance and the control of the plasma potassium concentration. Medicine (Baltimore). 1981 ; 60 (5), 339-54.
PubMed
11) Crop MJ, Hoorn EJ, et al. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant. 2007 ; 22 (12) : 3471-7.
PubMed
12) Ahmed I, Chilimuri SS. Fatal dysrhythmia following potassium replacement for hypokalemic periodic paralysis. West J Emerg Med. 2010 ; 11 (1) : 57-9.
PubMed
13) Whang R, Flink EB, et al. Magnesium depletion as a cause of refractory potassium repletion. Arch Intern Med. 1985 ; 145 (9) : 1686-9.
PubMed
14) Montague BT, Ouellette JR, et al. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008 ; 3 (2), 324-30.
PubMed
15) Clase CM, Carrero JJ, et al. Potassium homeostasis and management of dyskalemia in kidney diseases : conclusions from a Kidney Disease : Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020 Jan ; 97 (1) : 42-61.
PubMed
16) Durfey N, Lehnhof B, et al. Severe Hyperkalemia : Can the Electrocardiogram Risk Stratify for Short-term Adverse Events?. West J Emerg Med. 2017 Aug ; 18 (5) : 963-71.
PubMed
17) Poggio R, Grancelli HO, et al. Understanding the risk of hyperkalaemia in heart failure : role of aldosterone antagonism. Postgrad Med J. 2010 ; 86 (1013) : 136-42.
PubMed
18) Allon M. Hyperkalemia in end-stage renal disease : mechanisms and management. J Am Soc Nephrol. 1995 ; 6 (4) : 1134-42.
PubMed
19) Rabelink TJ, Koomans HA, et al. Early and late adjustment to potassium loading in humans. Kidney Int. 1990 Nov ; 38 (5) : 942-7.
PubMed
20) Schaefer TJ, Wolford RW. Disorders of potassium. Emerg Med Clin North Am. 2005 ; 23 (3) : 723-47, viii-ix.
 
21) American Diabetes Association. 2. Classification and Diagnosis of Diabetes : Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 ; 43 (Suppl 1) : S14-31.
 
22) Palmer BF. A Physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis. 2010 ; 56 (2) : 387-93.
 
23) Shingarev R, Allon M. A physiologic-based approach to the treatment of acute hyperkalemia. Am J Kidney. 2010 ; 56 (3) : 578-84.
 
24) Bakris GL, Woods SD, et al. Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors : A Post Hoc Analysis of the AMETHYST-DN Clinical Trial. Kidney Med. 2021 Mar 13 ; 3 (3) : 360-7.
 

第5部 最後に慢性期の腎臓管理を押さえる

P.237 掲載の参考文献
1) 日本腎臓学会 (編). エビデンスに基づくCKD診療ガイドライン 2018. 東京医学社, 2018.
 
2) Levey AS, de Jong PE, et al. The definition, classification, and prognosis of chronic kidney disease : a KDIGO Controversies Conference report. Kidney Int. 2011 ; 80 (1) : 17-28.
PubMed
3) Ishani A, Grandits GA, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol.2006 ; 17 (5) : 1444-52.
 
4) Sridhar VS, Liu H, et al. Finerenone-A New Frontier in Renin-Angiotensin-Aldosterone System Inhibition in Diabetic Kidney Disease. Am J Kidney Dis. 2021 Aug ; 78 (2) : 309-11.
PubMed
5) Bakris GL, Agarwal R, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 ; 383 (23) : 2219-29.
PubMed
6) Imai E, Horio M, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007 ; 11 (2) : 156-63.
PubMed
7) 花房規男, 阿部雅紀, 他. わが国の慢性透析療法の現況 (2020年12月31日現在). 日本透析学会誌. 2021 ; 54 (12) : 626.
 
8) Imai E, Horio M, et al. Slower decline of glomerular filtration rate in the Japanese general population : a longitudinal 10-year follow-up study. Hypertens Res. 2008 ; 31 (3) : 433-41.
PubMed
9) Keith DS, Nichols GA, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004 ; 164 (6) : 659-63.
 
10) Ninomiya T, Kiyohara Y, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population : the Hisayama Study Kidney Int. 2005 : 68 (1) : 228-36.
 
11) Kovesdy CP. Significance of hypo- and hypernatremia in chronic kidney disease. Nephrol Dial Transplant. 2012 ; 27 (3) : 891-8.
PubMed
12) Einhorn LM, Zhan M, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009 ; 169 (12) : 1156-62.
PubMed
13) Bakris GL, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes : a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 ; 36 (3) : 646-61.
 
14) Upadhyay A, Earley A, et al. Systematic review : blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011 ; 154 (8) : 541-8.
PubMed
15) Ruggenenti P, Remuzzi G. Proteinuria : Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol. 2009 ; 5 (8) : 436-7.
PubMed
16) Iseki K, Ikemiya Y, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003 ; 63 (4) : 1468-74.
PubMed
17) Fried LF, Emanuele N, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013 ; 369 (20) : 1892-903.
PubMed
18) Parving HH, Lehnert H, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 ; 345 (12) : 870-8.
PubMed
19) Schmidt M, Mansfield KE, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks : cohort study. BMJ. 2017 ; 356 : j791.
PubMed
20) Silverberg D, Wexler D, et al. The cardio-renal anaemia syndrome : does it exist? Nephrol Dial Transplant. 2003 ; 18 (8) : viii7-12.
 
21) Perkovic V, Jardine MJ, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 ; 380 (24) : 2295-306.
PubMed
22) Wanner C, Inzucchi SE, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 ; 375 (4) : 323-34.
PubMed
23) Heerspink HJL, Stefansson BV, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 ; 383 (15) : 1436-46.
PubMed
24) Kovesdy CP, Anderson JE, et al. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant. 2009 ; 24 (4) : 1232-7.
PubMed
25) de Brito-Ashurst I, Varagunam M, et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009 ; 20 (9) : 2075-84.
PubMed
26) Mahajan A, Simoni J, et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 2010 ; 78 (3) : 303-9.
PubMed
27) Husted FC, Nolph KD. NaHCO3 and NaCl tolerance in chronic renal failure II. Clin Nephrol. 1977 ; 7 (1) : 21-5.
PubMed
28) Kusaba T, Mori Y, et al. Sodium restriction improves the gustatory threshold for salty taste in patients with chronic kidney disease. Kidney Int. 2009 ; 76 (6) : 638-43.
PubMed
29) Levey AS, Greene T, et al. Effect of dietary protein restriction on the progression of kidney disease : long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis. 2006 ; 48 (6) : 879-88.
PubMed
30) Brunori G, Viola BF, et al. Efficacy and safety of a ver y-low-protein diet when postponing dialysis in the elderly : a prospective randomized multicenter controlled Study. Am J Kidney Dis. 2007 ; 49 (5) : 569-80.
 
31) Kalantar-Zadeh K, Gutekunst L, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010 ; 5 (3) : 519-30.
PubMed
32) Goicoechea M, de Vinuesa SG, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010 ; 5 (8) : 1388-93.
PubMed
33) Iseki K, Ikemiya Y, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004 ; 44 (4) : 642-50.
 
34) Kimura K, Hosoya T, et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia : A Randomized Trial. Am J Kidney Dis. 2018 ; 72 (6) : 798-810.
PubMed
35) Badve SV, Pascoe EM, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020 ; 382 (26) : 2504-13.
PubMed
36) Doria A, Galecki AT, et al. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020 ; 382 (26) : 2493-503.
PubMed
P.255 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編). 高血圧治療ガイドライン 2019. ライフサイエンス出版, 2019.
 
2) Whelton PK, Carey RM, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 ; 71 (6) : e13-115.
 
3) SPRINT Research Group ; Jackson T Wright Jr, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26 ; 373 (22) : 2103-16.
 
4) Ohkubo T, Kikuya M, et al. Prognosis of "masked" hypertension and 'white-coat' hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005 ; 46 (3) : 508-15.
PubMed
5) Eguchi K, Hoshide S, et al. Is very low dose hydrochlorothiazide combined with candesartan effective in uncontrolled hypertensive patients? Blood Press Monit. 2010 Dec ; 15 (6) : 308-11.
PubMed
6) https://www.mhlw.go.jp/bunya/kenkou/dl/kenkounippon21_01.pdf.
 
7) Grigoryan L, Pavlik VN, et al. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulator y blood pressure and high medication adherence. J Am Soc Hypertens. Nov-Dec 2013 ; 7 (6) : 471-6.
 
8) Sinha AD, Agarwal R. Thiazides in advanced chronic kidney disease : time for a randomized controlled trial. Curr Opin Cardiol. 2015 ; 30 (4) : 366-72
 
9) Bakris GL, Williams M, et al. Preserving renal function in adults with hypertension and diabetes : a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 ; 36 (3) : 646-61.
 
10) Williamson JD, Supiano MA, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged > 75 Years : A Randomized Clinical Trial. JAMA, 2016 ; 315 (24) : 2673-82.
 
11) Zampaglione B, Pascale C, et al. Hypertensive urgencies and emergencies. Prevalence and clinical presentation. Hypertension 1996 ; 27 : 144-7.
PubMed
12) Astarita A, Covella M, et al. Hypertensive emergencies and urgencies in emergency departments : a systematic review and meta-analysis. J Hypertens. 2020 ; 38 (7) : 1203-10.
PubMed
P.269 掲載の参考文献
1) Sakamoto S, Miyazawa K, et al. Chronological changes in the epidemiological characteristics of upper urinary tract urolithiasis in Japan. Int J Urol. 2018 Apr ; 25 (4) : 373-8.
PubMed
2) Uribarri J, Oh MS & Carroll HJ. The first kidney stone. Ann Intern Med. 1989 Dec 15 ; 111 (12) : 1006-9.
 
3) Kohjimoto Y. et al. Association of metabolic syndrome traits and severity of kidney stones : results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis. 2013 Jun ; 61 (6) : 923-9.
PubMed
4) 日本泌尿器科学会, 日本泌尿器内視鏡学会, 日本尿路結石症学会 (編). 尿路結石症診療ガイドライン 第2版. 金原出版, 2013.
 
5) Taylor, EN, Stampfer MJ & Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005 Jan 26 ; 293 (4) : 455-62.
 
6) Ganesan C, Thomas IC, et al. Osteoporosis, Fractures, and Bone Mineral Density Screening in Veterans With Kidney Stone Disease. JBone Miner Res. 2021 May ; 36 (5) : 872-8.
 
7) Taylor EN, Feskanich D, et al. Nephrolithiasis and Risk of Incident Bone Fracture. J Urol. 2016 May ; 195 (5) : 1482-6.
PubMed
8) Lingeman JE, Woods JR & Toth PD. Blood pressure changes following extracorporeal shock wave lithotripsy and other forms of treatment for nephrolithiasis. JAMA. 1990 Apr 4 ; 263 (13) : 1789-94.
PubMed
9) Lingeman JE, Woods J, et al. The role of lithotripsy and its side effects. J Urol. 1989 Mar ; 141 (3 Pt 2) : 793-7
 
10) 山口聡. 尿路結石症と臨床検査. 生物試料分析 Vol. 32, No 3 (2009) p200-14.
 
11) Reungjui S, Prasongwatana V, et al. Magnesium status of patients with renal stones and its effect on urinary citrate excretion. BJU Int. 2002 Nov ; 90 (7) : 635-9.
PubMed
12) https://www.jstage.jst.go.jp/article/gnam1999/27/2/27_107/_pdf/-char/ja.
 
13) Pearle MS, Roehrborn CG& Pak CY. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J. Endourol. 13, 679-685 (1999).
PubMed
14) Han H, Segal AM, et al. Nutritional Management of Kidney Stones (Nephrolithiasis). Clin Nutr Res. 2015 Jul ; 4 (3) : 137-52.
PubMed
15) Kleeman CR, Bohannan J, et al. Effect of variations in sodium intake on calcium excretion in normal humans. Proc Soc Exp Biol Med. 1964 Jan ; 115 : 29-32.
PubMed
16) Curhan G, Willett WC, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993 Mar 25 ; 328 (12) : 833-8.
 
17) Curhan GC, Willett WC, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med. 1997 Apr 1 ; 126 (7) : 497-504.
PubMed
18) Melmed S, Polonsky KS, et al. Williams Textbook of Endocrinology (Thirteenth Edition).Elsevier, 2016 ; 13章kidney stones : 1365-84.
 

書評

最近チェックした商品履歴

Loading...